Trevi therapeutics, inc. (TRVI)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Operating expenses:
Research and development

6,019

4,823

5,650

5,528

3,338

4,523

3,747

3,439

2,363

General and administrative

2,620

1,943

2,000

1,889

1,474

1,406

1,210

941

779

Total operating expenses

8,639

6,766

7,650

7,417

4,812

5,929

4,957

4,380

3,142

Loss from operations

-8,639

-6,766

-7,650

-7,417

-4,812

-5,929

-4,957

-4,380

-3,142

Other income (expense):
Change in fair value of Series C redeemable convertible preferred stock liability

-

-

-

-

-

137

702

422

844

Change in fair value of obligation for loan success fee

-

0

0

-163

-52

-11

-47

-68

-12

Interest income

157

225

280

229

58

46

27

38

45

Interest expense

-

-

-

-

-

0

0

51

123

Total other income (expense), net

157

225

280

66

6

-102

-722

-503

-934

Loss before income tax benefit

-8,482

-6,541

-7,370

-7,351

-4,806

-6,031

-5,679

-4,883

-4,076

Income tax benefit

-9

-4

-5

-5

-4

-49

-25

-25

-25

Net loss

-8,473

-6,537

-7,365

-7,346

-4,802

-5,982

-5,654

-4,858

-4,051

Accretion of redeemable convertible preferred stock

-

0

0

-1,332

-203

-96

96

-175

-195

Dividends accrued on redeemable convertible preferred stock

-

0

0

686

1,553

1,467

1,362

1,293

1,280

Adjusted net loss attributable to common stockholders

-8,473

-6,537

-7,365

-6,700

-6,152

-7,353

-7,112

-5,976

-5,136

Basic and diluted net loss per common share outstanding

-0.48

12.61

-0.41

-0.63

-13.85

-16.78

-16.22

-13.62

-11.82

Weighted average common shares used in net loss per share attributable to common stockholders, basic and diluted

17,834

18,092

17,834

10,571

444

438

438

438

434